Markets

Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed

Aug 27, 2026 · 05:54 PM ET· updated 58m ago

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the

Why It Matters

Gilead got approval for a new HIV medicine that's smaller and easier to take once a day. This shows the company is creating helpful new products, which is a sign of a healthy business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GILD149.41

+1.32 (+0.89%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.